Apply to trial NCT06341296

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

To evaluate the objective response rate, disease control rate, progression-free survival, overall survival, surgical conversion rate and safety of irinotecan liposome combined with 5-FU/LV+ bevacizumab regimen in first-line treatment of advanced metastatic colorectal cancer patients.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening